Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation

Robert CG Martin123*, Prejesh Philips123, Susan Ellis123, David Hayes123 and Sandeep Bagla123

Author Affiliations

1 Department of Surgery, Division of Surgical Oncology, University of Louisville, 315 E. Broadway - #312, 40202 Louisville, KY, USA

2 Department of Interventional Radiology, Baptist Hospital, Little Rock, AK, USA

3 Department of Interventional Radiology, INOVA, Alexandria, VA, Egypt

For all author emails, please log on.

BMC Cancer 2014, 14:540  doi:10.1186/1471-2407-14-540

Published: 26 July 2014

Abstract

Background

Irreversible electroporation (IRE) has recently been added as an additional therapeutic ablative option in patients with locally advanced cancers (LAC) involving vital structures. IRE delivers localized electric current by peri-tumoral discrete probes to attain irreversible changes in cell membrane leading to cell death. The aim of this study was to evaluate the long-term effects of IRE in the treatment of locally advanced tumors.

Methods

A prospective IRB approved evaluation of 107 consecutive patients from 7 institutions with tumors that had vascular invasion treated with IRE from 5/2010 to 1/2012. LAC was defined as primary tumor with <5 mm from major vascular structure based on pre-operative dynamic imaging or intra-operative criteria.

Results

IRE as utilized in LAC in the liver (N = 42, 40%) and pancreas (N = 37, 35%), with a median number of lesions being 2 with a mean target size of 3 cm. IRE attributable morbidity rate was 13.3% (total 29.3%) with high-grade complications seen in 4.19% (total 12.6%). No significant vascular complications were seen, and of the high-grade complications, bleeding (2), biliary complications (3) and DVT/PE (3) were the most common. Complications were more likely with pancreatic lesions (p = 0.0001) and open surgery (p = 0.001). Calculated local recurrence free survival (LRFS) was 12.7 months with a median follow up of 26 months censured at last follow up. The tumor target size was inversely associated with recurrence free survival (b = 0.81, 95% CI: 1.6 to 4.7, p value = 0.02) but this did not have a significant overall survival impact.

Conclusions

IRE represents a novel therapeutic option in patients with LAC involving vital structures that are not amenable to surgical resection. Acceptable to high local disease control and the long LRFS can be achieved with this therapy in combination with other multi-disciplinary therapies.

Keywords:
Irreversible electroporation; Locally advanced tumors; Vascular invasion; Liver tumors; Pancreatic tumors; Safety